(Reuters) -Regeneron shares fell nearly 18% on Friday after its experimental drug for patients with a type of lung condition ...

Regeneron and partner Sanofi were studying the potential blockbuster drug, itepekimab, as a treatment for chronic obstructive ...

Recent research from Sanofi highlights the significant impact of Type 1 Diabetes on those living with the conditionThe song, "Rise Up," shares their experiences of living with the condition ...

Sanofi and Vietnam Vaccine JSC, or VNVC, on Tuesday launched a vaccine manufacturing facility in Vietnam, aimed at producing ...

This browser is no longer supported at MarketWatch. For the best MarketWatch.com experience, please update to a modern browser.

Sanofi is acquiring Vigil Neuroscience, a biotech firm focused on novel neurodegenerative disease therapies, to boost its ...

Myasthenia gravis is an autoimmune disorder in which antibodies disrupt the communication between nerves and muscles, ...

The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...

McCain currently works at Kiniksa Pharmaceuticals Ltd., as Independent Director from 2018, Kiniksa Pharmaceuticals International Plc, as Independent Director from 2024, and Blueprint Medicines Corp., ...

Andretti and Marcus Ericsson drive Allegra into Indianapolis 500 as the 2022 winner and his team join the allergy brand for ...

According to the latest study from BCC Research, "Neurology Market: A BCC Research Overview" is estimated to increase from ...